NERV Minerva Neurosciences, Inc
Company Updates ·
Minerva reported GAAP net income of $17.5 million for the quarter, driven by a non-cash warrant gain, and cash, cash equivalents, marketable securities and restricted cash of approximately $75.4 million at June 30, 2026.
At its June 3, 2026 annual meeting, Minerva's stockholders approved two charter amendments, and the board adopted amended bylaws the same day.
Minerva signed a sales agreement with Leerink Partners LLC for up to $75.0 million of common stock, and its filing also says the roluperidone Phase 3 relapse phase now runs 52 weeks.
The company reported a GAAP net loss of $125.4 million for the quarter, including a $109.4 million non-cash warrant charge, and said the first patient was screened in March.
Vivo Capital LLC led the deal, which brings $80 million upfront in Series A preferred stock. The rest comes from two warrant tranches, and the larger one is tied to a Phase 3 roluperidone trial meeting its primary endpoint.
Minerva keeps its Nasdaq listing on a net income test, not an equity test, and now faces a one-year panel monitor. The company reported $21.5 million in cash at the end of 2024 and says it will need more capital.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $5.8 million | $11.9 million |
| Net income (loss) | -$293.4 million | $1.4 million |
| Cash from operations | -$13.5 million | -$19.6 million |
| Cash and equivalents | $82.3 million | $21.4 million |
Our latest story on this, dated May 27, 2026: "Minerva sets up $75 million at-the-market stock sale with Leerink Partners". The story links the filing or release it is based on. Read the story.
Minerva Neurosciences, Inc trades under the ticker NERV on NASDAQ.
Minerva Neurosciences, Inc is listed on NASDAQ. Our directory also records these other listings: GETTEX:4MNA; LS:A3DMH5; LSX:A3DMH5.
The SEC Central Index Key (CIK) for Minerva Neurosciences, Inc is 1598646. Its filings are on SEC EDGAR.
47,747,559 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-07.
Our directory records Minerva Neurosciences, Inc under United States.
Our directory classifies Minerva Neurosciences, Inc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Minerva Neurosciences, Inc is US6033802058.
aibio.space lists Minerva Neurosciences, Inc among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as MA.
Minerva Neurosciences, Inc reported a net loss of $293.4 million for the fiscal year ended Dec 31, 2025, and used $13.5 million of cash in operations, per its annual report to the SEC.
$5.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$75.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Minerva Neurosciences, dated Aug 7, 2026: "Minerva Neurosciences reports second quarter 2026 results and C19 trial progress". Minerva reported GAAP net income of $17.5 million for the quarter, driven by a non-cash warrant gain, and cash, cash equivalents, marketable securities and restricted cash of approximately $75.4 million at June 30, 2026. Source.
Our latest listing story, dated Mar 19, 2025: "Minerva Neurosciences keeps Nasdaq listing after meeting $500,000 net income rule". Minerva keeps its Nasdaq listing on a net income test, not an equity test, and now faces a one-year panel monitor. The company reported $21.5 million in cash at the end of 2024 and says it will need more capital. Source.
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio